Comparison of Decolonization of Methicillin-resistant Staphylococcus Aureus (MRSA) Using Theraworx
Not Applicable
Withdrawn
- Conditions
- Methicillin-Resistant Staphylococcus Aureus
- Interventions
- Other: Theraworx
- Registration Number
- NCT00713674
- Lead Sponsor
- Mercy Research
- Brief Summary
The purpose of this study is to examine treatment method of Methicillin-resistant Staphylococcus aureus (MRSA) decolonization in patients.
- Detailed Description
Decolonization therapy is indicated for management of patients with MRSA. Theraworx is reported to be an effective antimicrobial against multiple organisms. In this study, patients with positive MRSA colonization culture will be treated with Theraworx to evaluate decolonization duration capability.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Positive MRSA culture
Exclusion Criteria
- Patients currently on or start antibiotic therapy directed for MRSA.(Prophylaxis antibiotic for surgical procedure not considered therapy.)
- Patients with MRSA infected wounds
- Patients under the age of 18 years
- A woman currently pregnant or nursing a child
- Patients participating in another study within 30 days of randomization
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 Theraworx Theraworx intranasal 3 mupirocin antibiotic ointment mupirocin antibiotic ointment intranasal
- Primary Outcome Measures
Name Time Method Evidence of decolonization confirmed by intranasal culture Up to 14 days post treatment (+/- 1-2 days)
- Secondary Outcome Measures
Name Time Method Economic-Cost comparison of treatment Evidence of decolonization 5 days of treatment